Lee Wen-Shin, Lam Carson K, Manche Edward E
Department of Ophthalmology, Stanford University, Stanford, CA, USA.
Clin Ophthalmol. 2016 Dec 16;11:15-22. doi: 10.2147/OPTH.S122870. eCollection 2017.
The purpose of this study was to evaluate the long-term efficacy of phototherapeutic keratectomy (PTK) in treating epithelial basement membrane dystrophy (EBMD).
Preoperative and postoperative records were reviewed for 58 eyes of 51 patients with >3 months follow-up (range 3-170 months) treated for EBMD with PTK after failure of conservative medical treatment at Byers Eye Institute of Stanford University. Symptoms, clinical findings, and corrected distance visual acuity (CDVA) were assessed. The primary outcome measure was symptomatic recurrence as measured by erosions or visual complaints >3 months after successful PTK.
For eyes with visual disturbances (n=30), preoperative CDVA waŝ20/32 (0.24 Log-MAR, SD 0.21) and postoperative CDVA was ~20/25 (0.07 LogMAR, SD 0.12; <0.0001). Twenty-six eyes (86.7%) responded to treatment, with symptomatic recurrence in 6 eyes (23.1%) at an average of 37.7 months (SD 42.8). For eyes with painful erosions (n=29), preoperative CDVA was ~20/25 (0.12, SD 0.19) and postoperative CDVA was ~20/20 (0.05. SD 0.16; =0.0785). Twenty-three eyes (79.3%) responded to treatment, with symptomatic recurrence in 3 eyes (13.0%) at an average of 9.7 months (SD 1.5). The probability of being recurrence free after a successful treatment for visual disturbances and erosions at 5 years postoperatively was estimated at 83.0% (95% confidence interval 68.7%-97.0%) and 88.0% (95% confidence interval 65.3%-96.6%), respectively.
The majority of visual disturbances and painful erosions associated with EBMD respond to PTK. For those with a treatment response, symptomatic relief is maintained over long-term follow-up.
本研究旨在评估光治疗性角膜切除术(PTK)治疗上皮基底膜营养不良(EBMD)的长期疗效。
回顾了斯坦福大学拜尔斯眼科研究所对51例患者的58只眼睛进行PTK治疗EBMD的术前和术后记录,这些患者在保守药物治疗失败后接受治疗,随访时间超过3个月(范围3 - 170个月)。评估了症状、临床发现和矫正远视力(CDVA)。主要结局指标是成功进行PTK后3个月以上出现糜烂或视力问题所衡量的症状复发情况。
对于有视觉障碍的眼睛(n = 30),术前CDVA为20/32(0.24 Log - MAR,标准差0.21),术后CDVA约为20/25(0.07 LogMAR,标准差0.12;P < 0.0001)。26只眼睛(86.7%)对治疗有反应,6只眼睛(23.1%)出现症状复发,平均复发时间为37.7个月(标准差42.8)。对于有疼痛性糜烂的眼睛(n = 29),术前CDVA约为20/25(0.12,标准差0.19),术后CDVA约为20/20(0.05,标准差0.16;P = 0.0785)。23只眼睛(79.3%)对治疗有反应,3只眼睛(13.0%)出现症状复发,平均复发时间为9.7个月(标准差1.5)。术后5年,成功治疗视觉障碍和糜烂后无复发的概率估计分别为83.0%(95%置信区间68.7% - 97.0%)和88.0%(95%置信区间65.3% - 96.6%)。
大多数与EBMD相关的视觉障碍和疼痛性糜烂对PTK有反应。对于有治疗反应的患者,在长期随访中症状得到缓解。